ANI, “In the context of COVID-19 where there is a constant shift of variant of concerns mRNA vaccine is quickly redesigned." "...During a previous vaccine and COVID seems to be less effective and then people get worried.
So, this platform gives you an opportunity to quickly rehash your platform to the new variant in a very short time. Other conventional platforms have a more, a bit longer turnaround time to adapt to the new variants, but this one does which is a major advantage," he said. “The west was using only mRNA vaccine for the pandemic, but somehow it never got to other countries." He also said that these vaccines are cost-effective. "The second advantage is the cost of infrastructure.
You can come up with the same million kinds of numbers of doses in a much smaller setup. The flexibility and the lower input costs set us to go for it and we basically want to demonstrate that we can do it," Dr Rao added.
The vaccine platform holds promise for many infectious diseases that India centric like malaria or dengue or tuberculosis. "We also know this particular platform is very useful for other diseases, especially ones that are India centric, like malaria or dengue or tuberculosis because this was not a tested platform before COVID in a big public way.